Information Provided By:
Fly News Breaks for July 29, 2019
GHDX, EXAS
Jul 29, 2019 | 09:54 EDT
Piper Jaffray analyst William Quirk downgraded Genomic Health (GHDX) to Neutral from Overweight with an unchanged price target of $72. The analyst cites Exact Science's (EXAS) intent to acquire Genomic a cash and stock deal valued at $72 per share for the downgrade.